Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200026/S020

Abre Venous Self-expanding Stent System

Medtronic Vascular, Inc. · Decision date Oct 30, 2026

FDA DECISIONP200026/S020

What did the FDA approve?

FDA records P200026/S020 as a supplement to PMA P200026, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Oct 30, 2026.

FDA approval order statement

which requested approval to add instructions for user disassembly of the device to facilitate manual deployment in the event of partial stent deployment.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Oct 30, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P200026/S020
Regulatory pathway
PMA supplement
Product code
QAN
Decision code
APPR
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, iliac vein.

Product code
QAN
FDA device class
3

For the original device and its historical approval scope, see PMA P200026. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200026 · Original PMA

    Abre Venous Self-expanding Stent System

  2. P200026/S020 received

    Application receipt date recorded by FDA.

  3. P200026/S019 · Related supplement

    Abre Venous Self-Expanding Stent System

  4. P200026/S020 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P200026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200026

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Vascular, Inc.PMA approvalOct 21, 2020FDA
Medtronic Vascular, Inc.PMA supplementOct 16, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3033 Campus Dr., Plymouth, MN, 55441

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records